Article

CML in the Very Elderly: The Impact of Comorbidities and TKI Selection in a Real-life Multicenter Study

2024-03-13

Abstract excerpt

<title>Abstract</title> <p>Tyrosine kinase inhibitors (TKIs) have greatly improved chronic myeloid leukemia (CML) treatments, with survival rates close to the general population. Yet, for the very elderly, robust data remains limited. This study focused on assessing comorbidities, treatment approaches, responses, and survival for elderly CML patients. Our study was conducted on 123 elderly (≥ 75 years) CML patien...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 890de141-6221-5c45-be58-ba722c6c34c2
DOI: 10.21203/rs.3.rs-4003287/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

CML in the Very Elderly: The Impact of Comorbidities and TKI Selection in a Real-life Multicenter StudyDOI 10.21203/rs.3.rs-4003287/v1Read

Safety and Efficacy of TKIs in Very Elderly Patients (≥75 Years) with Chronic Myeloid LeukemiaSemantic proximity Read

Best First Line Tyrosine Kinase Inhibitor for Chronic Phase Chronic Myeloid Leukemia in Adults: A Network Meta-AnalysisSemantic proximity Read

Impact of First- and Second-Generation Tyrosine Kinase Inhibitors on the Development of Graft-Versus-Host Disease in Individuals with Chronic Myeloid Leukemia: A Retrospective Analysis on behalf of the Polish Adult Leukaemia GroupSemantic proximity Read

Clinical roundtable monograph: Unmet needs in the management of chronic myelogenous leukemia.Semantic proximity Read

The impact of pretransplant use of tyrosine kinase inhibitors on allogeneic stem cell transplantation in patients with chronic myeloid leukemia - A single-institution retrospective studySemantic proximity Read

Beyond Disease Control in Chronic Myeloid Leukemia: Real-World Quality of Life Across TKIs and Treatment-Free RemissionSemantic proximity Read

[Clinical Analysis for 42 Imatinib-resistant Patients with Chronic Myelogenous Leukemia].Semantic proximity Read

Dasatinib for the treatment of chronic myeloid leukemia: patient selection and special considerations.Semantic proximity Read

Update on the use of hydroxyurea for the early management of chronic-phase- chronic myeloid leukemia: data from a real-world cohortSemantic proximity Read

[Key points in second-line therapy for chronic myeloid leukemia].Semantic proximity Read

Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in older adultsSemantic proximity Read

Optimizing second-line therapy for chronic myeloid leukemia.Semantic proximity Read